SG11201500980WA - Clostridium difficile polypeptides as vaccine - Google Patents

Clostridium difficile polypeptides as vaccine

Info

Publication number
SG11201500980WA
SG11201500980WA SG11201500980WA SG11201500980WA SG11201500980WA SG 11201500980W A SG11201500980W A SG 11201500980WA SG 11201500980W A SG11201500980W A SG 11201500980WA SG 11201500980W A SG11201500980W A SG 11201500980WA SG 11201500980W A SG11201500980W A SG 11201500980WA
Authority
SG
Singapore
Prior art keywords
vaccine
clostridium difficile
polypeptides
difficile polypeptides
clostridium
Prior art date
Application number
SG11201500980WA
Other languages
English (en)
Inventor
Cesira Galeotti
Rosanna Leuzzi
Mariagrazia Pizza
Maria Scarselli
Meera Unnikrishnan
Manuele Martinelli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201216748A external-priority patent/GB201216748D0/en
Priority claimed from GB201216749A external-priority patent/GB201216749D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201500980WA publication Critical patent/SG11201500980WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201500980WA 2012-09-19 2013-09-19 Clostridium difficile polypeptides as vaccine SG11201500980WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201216748A GB201216748D0 (en) 2012-09-19 2012-09-19 Methods of treatment
GB201216749A GB201216749D0 (en) 2012-09-19 2012-09-19 Antigen combinations
PCT/IB2013/058673 WO2014045226A1 (en) 2012-09-19 2013-09-19 Clostridium difficile polypeptides as vaccine

Publications (1)

Publication Number Publication Date
SG11201500980WA true SG11201500980WA (en) 2015-04-29

Family

ID=49725168

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201500980WA SG11201500980WA (en) 2012-09-19 2013-09-19 Clostridium difficile polypeptides as vaccine

Country Status (13)

Country Link
US (1) US9932374B2 (enExample)
EP (1) EP2897637A1 (enExample)
JP (1) JP2015529677A (enExample)
KR (1) KR20150056540A (enExample)
CN (1) CN104582722A (enExample)
AU (1) AU2013319821A1 (enExample)
BR (1) BR112015004629A2 (enExample)
CA (1) CA2882620A1 (enExample)
IL (1) IL237172A0 (enExample)
MX (1) MX2015002485A (enExample)
RU (1) RU2015106916A (enExample)
SG (1) SG11201500980WA (enExample)
WO (1) WO2014045226A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391236B (es) 2011-04-22 2025-03-21 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos.
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
GB2525177A (en) * 2014-04-14 2015-10-21 New Royal Holloway & Bedford Vaccine
ES2870506T3 (es) 2015-02-19 2021-10-27 Immune Biosolutions Inc Antígeno y anticuerpo del epítopo de las toxinas a y/o b de clostridium difficile, y sus usos farmacéuticos
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
EP3810163A1 (en) 2018-06-19 2021-04-28 GlaxoSmithKline Biologicals SA Immunogenic composition
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU746859B2 (en) 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
EP1268774A2 (en) * 2000-03-21 2003-01-02 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
WO2001094599A1 (en) * 2000-06-07 2001-12-13 Smittskyddsinstitutet Gene expression cassette and its use
WO2002077183A2 (en) * 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
AU2003299527A1 (en) * 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
EP2167119B1 (en) * 2007-06-14 2016-08-24 The Secretary of State for Health Chemically modified peptides with improved immunogenicity
CA2714720A1 (en) * 2008-02-28 2009-09-03 3M Innovative Properties Company Antibodies to clostridium difficile spores and uses thereof
WO2011060431A2 (en) 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease
EP2519257A4 (en) * 2009-12-02 2014-10-15 Univ Tufts ATOXIC RECOMBINANT HOLOTOXINS FROM CLOSTRIDIUM DIFFICILE AS IMMUNOGENESIS
SG11201402375VA (en) 2011-12-08 2014-10-30 Novartis Ag Clostridium difficile toxin-based vaccine

Also Published As

Publication number Publication date
JP2015529677A (ja) 2015-10-08
EP2897637A1 (en) 2015-07-29
AU2013319821A1 (en) 2015-02-26
US9932374B2 (en) 2018-04-03
KR20150056540A (ko) 2015-05-26
BR112015004629A2 (pt) 2017-11-21
MX2015002485A (es) 2015-06-05
RU2015106916A (ru) 2016-11-10
US20150315248A1 (en) 2015-11-05
IL237172A0 (en) 2015-04-30
WO2014045226A1 (en) 2014-03-27
CA2882620A1 (en) 2014-03-27
CN104582722A (zh) 2015-04-29

Similar Documents

Publication Publication Date Title
IL291571A (en) cx3cr1 binding polypeptides
EP2807186A4 (en) DIFFICULT CLOSTRIDIUM VACCINES COMPRISING RECOMBINANT TOXINS
IL235890A0 (en) vaccine
GB201218427D0 (en) Blender
EP2857033A4 (en) PEPTIDE WITH SKIN PERMEATION
PL2647387T3 (pl) Kompozycja szczepionki
GB201220474D0 (en) Polypeptides
GB201223386D0 (en) Vaccine
IL232957A0 (en) A composition based on clostridium difficile toxin
SG11201406301TA (en) Clostridium difficile antigens
EP2925362A4 (en) ANTIBODIES DIRECTED AGAINST CLOSTRIDIUM DIFFICILE
GB201711697D0 (en) Blender
SG11201500980WA (en) Clostridium difficile polypeptides as vaccine
ZA201503127B (en) Peptides
GB201200555D0 (en) Peptide
GB201204868D0 (en) Peptides
IL237571A0 (en) Tiotropium preparations
GB201223114D0 (en) Novel peptide
GB201210226D0 (en) Vaccine
GB201202090D0 (en) Vaccine
DK2846829T3 (en) Vaccine combinations
HUE036243T2 (hu) PSF1-származék peptid
IL231661A0 (en) Clostridium difficile antibodies
GB201121149D0 (en) Clostridium difficile toxin-based vaccine
GB201220328D0 (en) Peptides